mobile, a couple of things. first, Pfizer stated they are getting out of ophthalmology, so they want to see these results before fetching the best price. Secondly, they are probably including the classic group because they have high hopes for the secondary endpoints (lesion mitigation) in all three classes, which have been largely ignored in the expectations. Isonep will most likely end up as a co-drug with Eylea of Lucentis, not a stand-alone. And as such, will be worth far more than this company is today. I say BUY!
Sentiment: Strong Buy
Thank you to all of you on this thread commenting - a much appreciated and thoughtful discussion that is absent on many other boards. I just wanted to add two thoughts. An exec at LPath reinforced that the phase 1 group was very heavily pretreated, which may explain why the classic group was disproportionally represented in the phase 1 study. 5 classic versus 3 occult/minimally classic is not at all representative of the wet AMD population, which is 3 classic to every 7 occult/minimally classic.
Unfortunately Pfizer insisted that all three groups be represented in the phase 2 study (If it were my study, I would have excluded the classic group), but still, the average letter improvement should be close to 9 in this study. More importantly (in my view) is that the lessening of the CNV and fibrotic lesions (secondary endpoints I believe) could be remarkable in the results, so if the letter improvement fails to impress, the secondaries may nonetheless.
I'm holding both CLDN and AAVL through results, and I heavied up today on CLDN, but will probably dump a considerable portion of CLDN prior to data release. The data is somewhat cloudy on CLDN, and there were only 8 subjects receiving the high dose. Little data is what we are dealing with on most of these gene therapy companies - BLUE has, what, 7 people treated for Beta Thalassemia? But even with 7, no transfusions looks pretty compelling. 83% reduction in cardio events also looks compelling for CLDN. I also got into ONCE. Another gene therapy ophthalmology company. I guess I'm into eyes for 2015!
well I've suspected. I can't keep them all straight: apokerace, macugen, sidelurker, bergy, etc. I wish message boards would limit registrations to 1 per IP address, and also not allow anonymous IP so you can't hide behind an anonymizer. Not sure how'd they deal with cell phones, but I'm sure there's a way.
dang I like your tough talkin', sidelurker. Makes me want to strap my six-shooters on, walk down main street, and go shoot up some butte!
Genfit's results are very mixed, but the trial failed without massaging the data. I'm out. I took a hit, although I got out by getting the news via Twitter before US investors, so I only took half of the drop.
I second the congrats on CNAT - I had it and let it go. May buy it back. I still have Genfit. That's a binary event coming up any day.
fininsun, mrk's drugs will be DOA. The market (i.e. the payers) wants something better if it's going to replace Harvoni. They want 6 and 8 week therapies, or even 4 week. One or possibly two combo pills. They want Achillion.
I'm with you Charles - this took me by surprise. However, I doubled my position. #$%$ far as the biotech sector goes, I'm not sure if we are in the first third of a 20%+ correction, or just another hiccup. I suspect the latter.
no particular reason other than its a conference and it's BLUE out there talking. Last public comment on SCD was Dec 9 that the SCD patient achieved neutrophil engraftment. We are now another 3-4 months out and so I'm thinking they may make a comment about how the patient is doing, without having any conclusions yet.
thanks Magnam! I have to admit, I haven't done full DD on Esperion, other than looking at the data from last trial. I bought today purely because of the $15 drop to $87. It might drop to $80-84, in which case I may buy more.
last four trading days are higher than average volume. Today is 233% of average volume. We may have a bit more to go but tomorrow it could snap back just as easily...